UCB to present new long-term data for bimekizumab at EULAR 2023

31 May 2023

Belgium’s largest drugmaker UCB (Euronext: UCB) will present new long-term 52-week data from three Phase III studies of bimekizumab at the 2023 meeting of the European Congress of Rheumatology (EULAR).

Approved in Europe since 2021 in plaque psoriasis, the interleukin (IL)-17F and IL-17A blocking antibody is marketed in those indications under the Bimzelx brand.

The US regulator has accepted a resubmission in plaque psoriasis, and is expected to reach a decision in the coming months.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK